CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), designed to stimulate the pituitary gland to increase natural secretion of growth hormone (GH). Unlike native GHRH, CJC-1295 has been modified with a Drug Affinity Complex (DAC), which extends its half-life significantlyāfrom minutes to more than 7 daysāallowing for weekly rather than multiple daily injections.This extended activity makes CJC-1295 particularly valuable in protocols targeting fat loss, muscle growth, improved sleep, and anti-aging benefits, as it mimics the pulsatile GH release pattern, rather than overwhelming the system with exogenous GH.
What the Science Says: Summary of Key Studies
Long-Acting GH-Releasing Hormone Analogue in Humans
In a landmark clinical study by Teichman et al., healthy volunteers received subcutaneous injections of CJC-1295. The results showed:
- A two- to ten-fold increase in mean GH levels for up to 6 days after a single injection.
- A significant elevation of IGF-1 (Insulin-like Growth Factor 1) that lasted for up to 10 days.
- No evidence of desensitization or pituitary suppression, even with repeated dosing.
Mechanism Behind the Long Half-Life - CJC-1295ās extended half-life is made possible by covalent binding to albumin, which protects it from enzymatic degradation and rapid renal clearance. This mechanism avoids frequent spikes and mimics a more physiological GH profile.
Synergy with GHRP-6 or Ipamorelin - Several animal and clinical studies suggest that combining CJC-1295 with growth hormone secretagogues (GHS) like GHRP-6 or Ipamorelin enhances the pulsatile GH release through dual receptor activationāone targeting the GHRH receptor, the other targeting the ghrelin receptor. This mimics natural GH pulses, with lower risk of desensitization.
By enhancing natural hormone function, CJC-1295 offers a regulated and more physiological path to performance and wellnessāsupported by both pharmacokinetics and clinical outcomes.